ROME – Strategies that combine conventional synthetic disease-modifying antirheumatic drugs, such as methotrexate, sulfasalazine, or leflunomide, with a tapered glucocorticoid regimen to rapidly...
ROME – Strategies that combine conventional synthetic disease-modifying antirheumatic drugs, such as methotrexate, sulfasalazine, or leflunomide, with a tapered glucocorticoid regimen to rapidly...
ROME – Knee joint distraction – a method of relieving mechanical stress on the joint by temporarily pinning it – could help some patients with osteoarthritis avoid the need for a knee...
ROME – New therapies introduced over the past 15 years have vastly improved the lives of patients with rheumatic diseases but are also creating complex treatment scenarios as more female patients...
VANCOUVER, B.C. – Amgen’s recent announcement that it is pulling the plug on further development of the investigational interleukin-17 receptor A inhibitor brodalumab was the red hot topic among...
VANCOUVER, B.C. – Amgen’s recent announcement that it is pulling the plug on further development of the investigational interleukin-17 receptor A inhibitor brodalumab was the red hot topic among...
ROME – The rate of adverse events in patients with juvenile idiopathic arthritis appears to climb with the use of more than one biologic agent over time, Dr. Joost Swart reported at the European...
ROME – Reassuring new data from the German biologics registry RABBIT presented at the European Congress of Rheumatology indicate that exposure to biologic therapies around the time of conception does...
ROME – Updated expert recommendations from the European League Against Rheumatism for the treatment of systemic sclerosis will focus on several new treatment options, although the use of biologic...
SEATTLE – When it comes to managing osteoarthritis, clinicians can use their interactions with patients to tap into a powerful placebo effect, according to Dr. Paul Dieppe, a professor of health and...
